| 000 | 01855 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517020641.0 | ||
| 264 | 0 | _c20160222 | |
| 008 | 201602s 0 0 eng d | ||
| 022 | _a1537-6591 | ||
| 024 | 7 |
_a10.1093/cid/civ155 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLuetkemeyer, Anne F | |
| 245 | 0 | 0 |
_aCombined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. _h[electronic resource] |
| 260 |
_bClinical infectious diseases : an official publication of the Infectious Diseases Society of America _cJun 2015 |
||
| 300 |
_a1860-3 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAlkynes |
| 650 | 0 | 4 |
_aAntitubercular Agents _xblood |
| 650 | 0 | 4 |
_aArylamine N-Acetyltransferase _xgenetics |
| 650 | 0 | 4 |
_aBenzoxazines _xblood |
| 650 | 0 | 4 | _aCyclopropanes |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2B6 _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHIV Infections _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aPeru |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 |
_aRifampin _xtherapeutic use |
| 650 | 0 | 4 | _aSouth Africa |
| 650 | 0 | 4 |
_aTuberculosis _xcomplications |
| 650 | 0 | 4 | _aUganda |
| 700 | 1 | _aRosenkranz, Susan L | |
| 700 | 1 | _aLu, Darlene | |
| 700 | 1 | _aGrinsztejn, Beatriz | |
| 700 | 1 | _aSanchez, Jorge | |
| 700 | 1 | _aSsemmanda, Michael | |
| 700 | 1 | _aSanne, Ian | |
| 700 | 1 | _aMcIlleron, Helen | |
| 700 | 1 | _aHavlir, Diane V | |
| 700 | 1 | _aHaas, David W | |
| 773 | 0 |
_tClinical infectious diseases : an official publication of the Infectious Diseases Society of America _gvol. 60 _gno. 12 _gp. 1860-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/cid/civ155 _zAvailable from publisher's website |
| 999 |
_c24660580 _d24660580 |
||